207 related articles for article (PubMed ID: 15226124)
1. Improving topical microbicide applicators for use in resource-poor settings.
Vail JG; Cohen JA; Kelly KL
Am J Public Health; 2004 Jul; 94(7):1089-92. PubMed ID: 15226124
[TBL] [Abstract][Full Text] [Related]
2. Vaginal microbicides.
O'Brien RF
Adolesc Med Clin; 2006 Oct; 17(3):673-85; abstract xi. PubMed ID: 17030285
[TBL] [Abstract][Full Text] [Related]
3. AIDS research. Microbicide fails to protect against HIV.
Cohen J
Science; 2008 Feb; 319(5866):1026-7. PubMed ID: 18292313
[No Abstract] [Full Text] [Related]
4. News from the Society for Women's Health Research: seeking effective topical microbicides.
Greenberger P
J Womens Health Gend Based Med; 2001 Mar; 10(2):99-100. PubMed ID: 11268294
[No Abstract] [Full Text] [Related]
5. Acceptability of a carrageenan-based candidate vaginal microbicide and matching placebo: findings from a phase II safety trial among women in Chiang Rai, Thailand.
Jones HE; Chaikummao S; van de Wijgert JH; Friedland BA; Manopaiboon C; Witwatwongwana P; Wankrairot M; Chantharojwong N; Kilmarx PH
J Womens Health (Larchmt); 2009 Jul; 18(7):1003-10. PubMed ID: 19575689
[TBL] [Abstract][Full Text] [Related]
6. A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
Cohen JA; Brache V; Foster J; Cochon L; Callahan M; Schwartz J
Sex Transm Dis; 2013 Jun; 40(6):476-81. PubMed ID: 23677021
[TBL] [Abstract][Full Text] [Related]
7. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
Rosen RK; Morrow KM; Carballo-Diéguez A; Mantell JE; Hoffman S; Gai F; Maslankowski L; El-Sadr WM; Mayer KH
J Womens Health (Larchmt); 2008 Apr; 17(3):383-92. PubMed ID: 18328009
[TBL] [Abstract][Full Text] [Related]
8. Overcoming recruitment challenges: lessons learned from a safety and feasibility study of a diaphragm/microbicide combination in South Africa.
Guest G; Severy L; von Mollendorf C; Van Damme L
J Acquir Immune Defic Syndr; 2007 Aug; 45(4):481-2. PubMed ID: 17622839
[No Abstract] [Full Text] [Related]
9. HIV topical microbicides: the current development strategy is fully justified.
Stone AB
Am J Public Health; 2004 Nov; 94(11):1845-6; author reply 1846-7. PubMed ID: 15514217
[No Abstract] [Full Text] [Related]
10. Design aspects of vaginal applicators that influence acceptance among target users.
Bakke AJ; Zaveri T; Higgins MJ; Ziegler GR; Hayes JE
Sci Rep; 2021 May; 11(1):9802. PubMed ID: 33963262
[TBL] [Abstract][Full Text] [Related]
11. User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.
Morrow KM; Underhill K; van den Berg JJ; Vargas S; Rosen RK; Katz DF
Arch Sex Behav; 2014 Oct; 43(7):1459-67. PubMed ID: 24452632
[TBL] [Abstract][Full Text] [Related]
12. The need for a "condoms-only" control group in microbicide trials.
Jones H; van de Wijgert J; Kelvin E
Epidemiology; 2003 Jul; 14(4):505; author reply 505-6. PubMed ID: 12843779
[No Abstract] [Full Text] [Related]
13. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.
Garg S; Goldman D; Krumme M; Rohan LC; Smoot S; Friend DR
Antiviral Res; 2010 Dec; 88 Suppl 1():S19-29. PubMed ID: 21109064
[TBL] [Abstract][Full Text] [Related]
14. Preclinical assessments of vaginal microbicide candidate safety and efficacy.
Fernández-Romero JA; Teleshova N; Zydowsky TM; Robbiani M
Adv Drug Deliv Rev; 2015 Sep; 92():27-38. PubMed ID: 25543007
[TBL] [Abstract][Full Text] [Related]
15. The design of prophylactic trials for HIV: the case of microbicides.
Stein ZA; Myer L; Susser M
Epidemiology; 2003 Jan; 14(1):80-3; discussion 83-4. PubMed ID: 12500050
[No Abstract] [Full Text] [Related]
16. "Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels.
van den Berg JJ; Rosen RK; Bregman DE; Thompson LA; Jensen KM; Kiser PF; Katz DF; Buckheit K; Buckheit RW; Morrow KM
AIDS Behav; 2014 May; 18(5):862-70. PubMed ID: 24248674
[TBL] [Abstract][Full Text] [Related]
17. The slow evolution of microbicides for STD/HIV prevention.
Howes J; Bass M
J Gend Specif Med; 1999; 2(3):22-3. PubMed ID: 11252848
[No Abstract] [Full Text] [Related]
18. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
Catalone BJ; Kish-Catalone TM; Budgeon LR; Neely EB; Ferguson M; Krebs FC; Howett MK; Labib M; Rando R; Wigdahl B
Antimicrob Agents Chemother; 2004 May; 48(5):1837-47. PubMed ID: 15105142
[TBL] [Abstract][Full Text] [Related]
19. 'The study has taught me to be supportive of her': empowering women and involving men in microbicide research.
Venables E; Stadler J
Cult Health Sex; 2012; 14(2):181-94. PubMed ID: 22085043
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.
Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Domingo MC; Giguère JF; Piret J; Mwatha A; Mâsse B; Bergeron MG
Contraception; 2010 Jan; 81(1):79-85. PubMed ID: 20004278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
